Abstract 1878P
Background
Routine Electronic Monitoring of HRQoL (REMOQOL) in daily clinical care with real-time feedback to physicians could help to enhance patient-centered care. We evaluated the feasibility of REMOQOL for patients with aRCC treated with TKI.
Methods
QUANARIE study (NCT03062410) is an interventional, prospective, multicenter trial involving nine French oncological centres. Patients diagnosed with aRCC initiating first-line treatment with an anti-VEGFR TKI (Sunitinib or Pazopanib) were invited to complete the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 cancer-specific questionnaire before each visit with the physician on tablets and/or computers in the hospital or at home. During the visit, physicians had real-time access to HRQoL scores. The primary objective was to assess the proportion of patients having good compliance (>66% of questionnaires filled) with REMOQOL during the first 12 months. We hypothesized that 80% of patients having good compliance with REMOQOL would be meaningful, and as defined by Fleming’s one-stage design and defined parameters, we used data of the first 45 evaluable patients.
Results
Between April 2017 and September 2018, 45 patients were included in the primary objective analysis population: 25 treated with Sunitinib and 20 with Pazopanib. Mean age of evaluable patients was 65.5 years, and 72% (n=36) were male. During the first 12 months, the median number of HRQoL assessments was 10 (IQR 7-14), 60% were completed at home. At baseline burden of symptoms were higher for fatigue, sleep disturbance and pain The proportion of patients with a good compliance rate was 97.8% (n=44/45). Thirty patients (66.7%) had a compliance rate of 100%. Physicians checked the HRQoL results for 39.3% (n=265) of the visit.
Conclusions
The results of QUANARIE study suggest that REMOQOL is feasible in terms of patient’s compliance in the French context at a multicenter scale in a population of patients with aRCC receiving TKI. Further data concerning HRQoL results will be presented at the meeting.
Clinical trial identification
NCT03062410.
Editorial acknowledgement
Legal entity responsible for the study
CHU Minjoz.
Funding
Novartis.
Disclosure
G. Mouillet: Honoraria (self), Research grant/Funding (institution): Novartis; Honoraria (self), Travel/Accommodation/Expenses: Pfizer; Honoraria (self): BMS. P. Barthélémy: Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Novartis; Ipsen; MSD; BMS; Roche. L. Geoffrois: Honoraria (self), Travel/Accommodation/Expenses: Pfizer. S. Ladoire: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Novartis; Honoraria (self), Advisory/Consultancy: Pfizer; BMS; Ipsen; Roche. J-C. Eymard: Honoraria (self), Travel/Accommodation/Expenses: Pfizer. U. Stein: Honoraria (self): Novartis; Pfizer. A. Thiery-Vuillemin: Honoraria (self), Honoraria (institution): Pfizer; Honoraria (self): Novartis; BMS; MSD; Roche. All other authors have declared no conflicts of interest.